Comparative Pharmacology
Head-to-head clinical analysis: CARIPRAZINE HYDROCHLORIDE versus QUETIAPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARIPRAZINE HYDROCHLORIDE versus QUETIAPINE.
CARIPRAZINE HYDROCHLORIDE vs Quetiapine
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cariprazine is a partial agonist at dopamine D3 and D2 receptors, with higher affinity for D3 receptors, and a partial agonist at serotonin 5-HT1A receptors; it is an antagonist at 5-HT2A and 5-HT2B receptors.
Antagonist at serotonin 5-HT2A, dopamine D2, histamine H1, and adrenergic α1 receptors; weak partial agonist at 5-HT1A and serotonin transporter.
1.5 mg orally once daily, with a recommended titration starting at 1.5 mg on day 1, increased to 3 mg on day 2, then 4.5 mg on day 3, and 6 mg on day 4; target dose range: 1.5–6 mg once daily, with a maximum of 6 mg/day.
Initial: 25 mg PO BID, titrate to effective range 150-750 mg/day divided BID-TID; schizophrenia: 150-750 mg/day, bipolar disorder: 400-800 mg/day, major depressive disorder (adjunct): 150-300 mg/day at bedtime.
None Documented
None Documented
Clinical Note
moderateQuetiapine + Levofloxacin
"Quetiapine may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderateQuetiapine + Norfloxacin
"Quetiapine may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateQuetiapine + Gemifloxacin
"Quetiapine may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderateQuetiapine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Quetiapine is combined with Fluticasone propionate."
Terminal elimination half-life: 2–5 days (48–120 hours) for cariprazine and its major active metabolites (desmethylcariprazine, didesmethylcariprazine). The long half-life supports once-daily dosing and allows for gradual dose titration.
Terminal elimination half-life: ~6-7 hours (parent drug); extended-release: ~7 hours. Clinically, dosing is twice daily for immediate-release; once daily for extended-release.
Primarily hepatic metabolism via CYP3A4 and CYP2D6, with 60% excreted in feces (mostly as metabolites) and 30% in urine (mostly as metabolites). Less than 1% excreted unchanged.
Renal: 73% (as metabolites), Fecal: 20% (as metabolites), unchanged drug: <1% renal
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic